Home › Glioblastoma › Nebraska › Omaha
Glioblastoma clinical trials in Omaha, NE
5 studies for Glioblastoma are looking for participants at sites in and around Omaha (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII
RecruitingPhase 2
- University of Nebraska Medical Center, Omaha
A Study of Temodar With Abexinostat (PCI-24781) for Patients With Recurrent Glioma
RecruitingPhase 1
- University of Nebraska Medical Center, Omaha
Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors
RecruitingPhase 1
- Nebraska Cancer Specialists (Midwest Cancer Center - Legacy), Omaha
- XCancer Omaha / Urology Cancer Center, Omaha
Treatment of Patients With Recurrent High-Grade Glioma With APG-157 and Bevacizumab
RecruitingPhase 1/2
- University of Nebraska Medical Center, Omaha
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
RecruitingObservational study
- Massive Bio SYNERGY-AI site, Omaha
Glioblastoma trials in other cities
- New York City, NY30 studies
- Boston, MA28 studies
- Houston, TX25 studies
- Los Angeles, CA23 studies
- Durham, NC20 studies
- San Francisco, CA17 studies
- Washington, DC15 studies
- Rochester, MN15 studies
- Chicago, IL15 studies
- Miami, FL14 studies
- Columbus, OH14 studies
- Jacksonville, FL13 studies
Other studies in Omaha
- Prostate Cancer27 studies
- Non-Small Cell Lung Cancer24 studies
- Breast Cancer22 studies
- Colorectal Cancer18 studies
- Cancer (all types)18 studies
- Multiple Myeloma16 studies
- Non-Hodgkin Lymphoma14 studies
- Ovarian Cancer14 studies
- Pancreatic Cancer14 studies
- Head and Neck Squamous Cell Carcinoma13 studies
- Heart Failure13 studies
- Metastatic Cancer13 studies
From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.